Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with KEYTRUDA's growth plateauing and the company facing a significant patent cliff. Merck is focusing on diversifying its portfolio with new launches like Lipvendra but faces uncertainty in timing and growth durability. Lilly's robust pipeline and raised guidance position it as a more durable growth story through 2030, while Merck may appeal more to value investors due to its lower valuation and dividend yield.
Following the contrasting growth stories of Eli Lilly and Merck, Eli Lilly's stock on Pluang is trading at USD 1,155.65 with a 1.57% gain as of Sep 15, 2026 19:16 WIB, reflecting strong investor interest. Merck's shares are priced at USD 143.80, down slightly by 0.13% at the same time, highlighting a more cautious market stance. Eli Lilly's market cap stands at $1.01 trillion, significantly larger than Merck's $357.37 billion, underscoring its dominant position in the health sector.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
